Data on Colon Cancer Described by Researchers at Ohio State University (Financial Impact of Out-of-pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma): Oncology – Colon Cancer

NewsRx Medical Devices Daily

2022 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Medical Devices Daily -- Investigators publish new report on Oncology - Colon Cancer. According to news reporting originating from Columbus, Ohio, by NewsRx editors, the research stated, “Little is known about the societal burden of cancer surgical care in terms of out-of-pocket (OOP) costs. The current study sought to define OOP costs incurred by patients undergoing colorectal cancer resection.”

Our news editors obtained a quote from the research from Ohio State University, “Privately insured patients undergoing colorectal cancer resection between 2013 and 2017 were identified from the IBM MarketScan database. Total and OOP costs were calculated within 1 year prior to and 1 year post surgery. A multivariable linear regression model was used to estimate total OOP costs relative to patient demographic and clinical characteristics. Among 10,935 patients, 7289 (66.7%) had primary colon cancer while 3643 (33.3%) had rectal cancer. Median total costs were US$93,967 (IQR US$51027-168,251). Median OOP costs were US$4417 (IQR US$2519-6943), or 4.5% (IQR 2.2-8.1%) of total costs. OOP costs varied over the course of patient care; specifically, median OOP costs in the preoperative period were US$432 (IQR US$130-1452) versus US$2146 (IQR US$851-3525) in the perioperative period and US$969 (IQR US$327-2239) in the postoperative period. On multivariable analysis, receipt of chemotherapy (+US$1368, 95%CI +US$1211 to +US$1525) or radiotherapy (+US$842, 95% CI +US$626 to +US$1059) was associated with higher total OOP costs. Patients with a health maintenance organization (HMO) (-US$2119, 95% CI -US$2550 to -US$1689) or a point-of-service plan (-US$938, 95% CI -US$1385 to -US$491) had lower total OOP costs than patients with comprehensive insurance. In contrast, patients with a consumer-driven or a high-deductible health plan had considerably higher total OOP costs than patients with comprehensive insurance (+US$1400, 95% CI +US$972 to +US$1827 and +US$3243, 95% CI +US$2767 to +US$3717, respectively). Privately insured colorectal cancer patients undergoing surgical resection pay a median of US$4417 in OOP costs, or 4.5% of total costs.”

According to the news editors, the research concluded: “OOP costs varied with receipt of chemotherapy or radiotherapy, region of residence, and insurance plan type.”

This research has been peer-reviewed.

For more information on this research see: Financial Impact of Out-of-pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. Annals of Surgical Oncology, 2022. Annals of Surgical Oncology can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Annals of Surgical Oncology - http://www.springerlink.com/content/1068-9265/)

The news editors report that additional information may be obtained by contacting Timothy M. Pawlik, Ohio State University, Dept. of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1245/s10434-022-11755-2. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.